We are live on ! Find out more
Marshall Wace

Marshall Wace Portfolio holdings

AUM $100B
1-Year Est. Return 35.1%
This Fund
S&P 500
This Quarter Est. Return
+22.23%
1 Year Est. Return
+35.1%
3 Year Est. Return
+111.04%
5 Year Est. Return
+146.93%
10 Year Est. Return
+631.22%
AUM
$18.5B
AUM Growth
+$2.83B
Cap. Flow
+$342M
Cap. Flow %
1.85%
Top 10 Hldgs %
16.55%
Holding
2,427
New
891
Increased
366
Reduced
546
Closed
599

Top Buys

Rank Stock Value
1
TMO icon
Thermo Fisher Scientific
TMO
+$163M
2
CCL icon
Carnival Corporation Ltd
CCL
+$137M
3
RGEN icon
Repligen
RGEN
+$104M
4
BIIB icon
Biogen
BIIB
+$104M
5
ZTS icon
Zoetis
ZTS
+$91.9M

Sector Composition

Rank Sector Weight
1 Healthcare 28.24%
2 Consumer Discretionary 12.89%
3 Financials 10.77%
4 Technology 9.62%
5 Industrials 4.73%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
WGO icon
1526
Winnebago Industries
WGO
$879M
$424K ﹤0.01%
7,066
-371,224
-98% -$20.2M
FTAI icon
1527
FTAI Aviation
FTAI
$22B
$422K ﹤0.01%
+21,080
New +$352K
INGN icon
1528
Inogen
INGN
$171M
$422K ﹤0.01%
9,436
-73,271
-89% -$2.53M
TWLO icon
1529
Twilio
TWLO
$29.5B
$422K ﹤0.01%
+1,246
New +$389K
CYH icon
1530
Community Health Systems
CYH
$383M
$421K ﹤0.01%
+56,669
New +$401K
FCX icon
1531
Freeport-McMoran
FCX
$90.2B
$421K ﹤0.01%
16,162
-152,963
-90% -$3.18M
GORO icon
1532
Goldgroup Mining Inc.
GORO
$162M
$421K ﹤0.01%
+144,648
New +$449K
PTVE
1533
DELISTED
Pactiv Evergreen Inc. Common stock
PTVE
$420K ﹤0.01%
+23,173
New +$358K
ENTA icon
1534
Enanta Pharmaceuticals
ENTA
$370M
$419K ﹤0.01%
9,952
-24,982
-72% -$1.1M
ARMK icon
1535
Aramark
ARMK
$15.2B
$418K ﹤0.01%
+15,029
New +$360K
NOW icon
1536
ServiceNow
NOW
$109B
$417K ﹤0.01%
+3,790
New +$394K
LMB icon
1537
Limbach Holdings
LMB
$886M
$416K ﹤0.01%
+33,750
New +$362K
SENEA icon
1538
Seneca Foods Class A
SENEA
$1.13B
$416K ﹤0.01%
10,424
-1,667
-14% -$67.4K
SIC
1539
DELISTED
Select Interior Concepts, Inc. Class A Common Stock
SIC
$415K ﹤0.01%
58,042
-45,893
-44% -$332K
ESNT icon
1540
Essent Group
ESNT
$6.12B
$414K ﹤0.01%
+9,577
New +$414K
SCHW
1541
Charles Schwab
SCHW
$181B
$414K ﹤0.01%
7,800
-92,696
-92% -$4.2M
KDMN
1542
DELISTED
Kadmon Holdings, Inc.
KDMN
$414K ﹤0.01%
99,870
-83,431
-46% -$329K
BMCH
1543
DELISTED
BMC Stock Holdings, Inc
BMCH
$413K ﹤0.01%
+7,685
New +$356K
AVY icon
1544
Avery Dennison
AVY
$12.5B
$412K ﹤0.01%
+2,658
New +$385K
CWK icon
1545
Cushman & Wakefield Ltd
CWK
$3.07B
$411K ﹤0.01%
27,742
-68,074
-71% -$945K
TEAM icon
1546
Atlassian
TEAM
$24.3B
$411K ﹤0.01%
1,759
-29,711
-94% -$6.28M
TRNO icon
1547
Terreno Realty
TRNO
$7.72B
$411K ﹤0.01%
7,025
-84,560
-92% -$4.95M
ELP
1548
DELISTED
Companhia Paranaense de Energia (COPEL)
ELP
$410K ﹤0.01%
71,633
-140,970
-66% -$713K
OXY icon
1549
Occidental Petroleum
OXY
$54.6B
$409K ﹤0.01%
23,615
-27,258
-54% -$374K
BPMC
1550
DELISTED
Blueprint Medicines
BPMC
$408K ﹤0.01%
3,642
-257,260
-99% -$27.1M

Similar funds

Marshall Wace's Q4 2020 Portfolio in Review

As of Q4 2020, Marshall Wace held 2,427 positions worth $18.5B, up 18% from $15.6B the previous quarter. Its ten largest holdings account for 17% of the portfolio.

Marshall Wace's Q4 2020 filing shows 891 new, 366 increased, 546 reduced and 599 closed positions. Its largest new stake was Natera: 911,254 shares worth $90.7M. The largest sale was Alphabet (Google) Class A, an estimated $173M.

By sector, the portfolio is most concentrated in Healthcare at 28% of assets, up from 24% a quarter earlier, followed by Consumer Discretionary and Financials.

  • Marshall Wace's largest Q4 2020 buy was Natera: 911,254 shares worth $90.7M.
  • Marshall Wace added most to Thermo Fisher Scientific in Q4 2020, an estimated $163M increase.
  • Marshall Wace's biggest Q4 2020 reduction was Alphabet (Google) Class A, cutting an estimated $173M.
  • Marshall Wace fully exited FedEx in Q4 2020, selling an estimated $69.6M.
  • Marshall Wace's ten largest holdings make up 17% of its $18.5B portfolio in Q4 2020.
  • Marshall Wace opened 891 new positions and closed 599 in Q4 2020.
  • Marshall Wace's portfolio value rose 18% quarter-over-quarter to $18.5B.

Based on Marshall Wace's 13F filing for Q4 2020, filed 16 Feb 2021.